ArticleLancet (London, England)2022
Closing the global vaccine equity gap: equitably distributed manufacturing.
Article in Lancet (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of gross domestic product with equitable access to childhood vaccines in 195 countries: a systematic review and meta-analysis.BMJ global health · 2025Pooled it
- Trump and mRNA technologies: global health risks and opportunities in vaccine manufacturing diversification.Cadernos de saude publica · 2026Article
- Nigeria's post-COVID-19 vaccine manufacturing ambitions: Opportunities and regional implications.Journal of public health in Africa · 2026Article
- Review
- Expanding modeling boundaries to design more resilient vaccine supply networks.Health care management science · 2025Article
- Global disparities in the introduction, scale-up, and effectiveness evaluation of COVID-19 vaccines.Nature communications · 2025Article
- Decolonizing global health: Africa's pursuit of pharmaceutical sovereignty.BMC health services research · 2025Review
- TB vaccine development: monitoring international patent filings to anticipate access challenges.Frontiers in public health · 2025Article
- mRNA vaccines for infectious diseases - advances, challenges and opportunities.Nature reviews. Drug discovery · 2024Review
- A brief review on the lessons learned from COVID-19 on drug discovery and research.Medicine and pharmacy reports · 2024Review
- Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models.Globalization and health · 2024Article
- Health equity requires transformational change: Financial incentives based on worn-out market thinking will not deliver.PLOS global public health · 2024Article
- Modeling Supply and Demand Dynamics of Vaccines against Epidemic-Prone Pathogens: Case Study of Ebola Virus Disease.Vaccines · 2023Article
- Pandemic preparedness requires collaboration between governments, funders and pharma.Nature medicine · 2023Article
- Article
- Africa (COVID-19) Vaccine Technology Transfer: Where Are We?Life (Basel, Switzerland) · 2023Review
- Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced from two different cell lines.bioRxiv : the preprint server for biology · 2023Article
- A targeted approach to vaccine hesitancy.Oxford open immunology · 2023Article
- TheiScience · 2022Article
- Vaccine equity in COVID-19: a meta-narrative review.BMJ global health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.